Drugs & 
Pill 
Interaction 
Side 
Conditions 
Treatment 
Compare 
My Med 
Discount 
FDA 
Price 
Phonetic 
Health Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Kisunla (donanemab-azbt) for the Treatment of Early Symptomatic Alzheimer's Disease
The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and...
FDA Approves Ahzantive (aflibercept-mrbb), a Biosimilar to Eylea
Planegg-Martinsried, Germany July 1, 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH (“Klinge”)...
FDA Approves Pyzchiva (ustekinumab-ttwe), a Biosimilar to Stelara
Basel, July 1, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA)...
FDA Approves Tepylute (thiotepa) Ready-to-Dilute Injectable Formulation to Treat Breast Cancer and Ovarian Cancer
(BUSINESS WIRE) June 28, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S....
FDA Approves Ohtuvayre (ensifentrine) for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD)
LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”),...
FDA Approves New Drug to Treat Alzheimer's
A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday.In clinical trials, donanemab (Kisunla) modestly...
U.S. Government to Pay Moderna $176 Million to Develop mRNA Flu Vaccine
U.S. health officials announced Tuesday that the federal government will pay Moderna $176 million to speed development of a pandemic flu vaccine based...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are considered,...
High Social Media Use Tied to Depression in Only Some Teens
High social media use is only tied to increased depression in teens who are already vulnerable, according to a study published online June 26 in the Journal...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3 in BMJ...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
Supreme Court to Hear Case Challenging FDA's Ban of Flavored Vapes
In a case that will test the U.S. Food and Drug Administration's authority to approve or reject new vaping products, the U.S. Supreme Court said Tuesday...
Tattoo Inks Can Be Contaminated With Bacteria: Study
TUESDAY, July 2, 2024 — Getting inked could make you sick. In a first-of-its-kind study, researchers detected bacteria in commercial tattoo and...
Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
DAEJEON, South Korea, July 2, 2024. PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next...
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today...
Monthly News Roundup - June 2024
FDA Grants Expanded Approval to Skyrizi for Ulcerative Colitis On June 18th, the U.S. Food and Drug Administration (FDA) approved AbbVie’s Skyrizi...
Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics";...
Scientists Spot Which Gut Germs Trigger Compulsive Eating
Specific types of gut bacteria appear to be linked to compulsive eating, a new study reports. Researchers found that one type of gut bacteria -- the Proteobacteria...
Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies Modified to Minimize Burden on Healthcare Delivery System
Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies Modified to Minimize Burden on Healthcare...
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
BASKING RIDGE, N.J. & RAHWAY, N.J., June 26, 2024 – The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for...
Recently Added
Recently added consumer and prescribing information: Ohtuvayre, Sofdra, Yimmugo, Iqirvo, Rytelo, mRESVIA, Bkemv, Yesafili, Myhibbin, Rezenopy
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex Carenotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Kisunla Kisunla (donanemab-azbt) is an amyloid beta-directed antibody indicated for the treatment of early symptomatic Alzheimer’s disease.
- Ahzantive Ahzantive (aflibercept-mrbb) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Eylea indicated for the treatment of...
- Pyzchiva Pyzchiva (ustekinumab-ttwe) is a human interleukin-12 and -23 antagonist biosimilar to Stelara used for the treatment of plaque psoriasis...
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to...
Drug Information
Tools
- Interaction Checker
- Pill Identifier
- Symptom Checker
- Medication Record
- Mobile Apps
- Drug Imprint Codes
- Community Support
- Compare Drugs
News & Alerts
- Medical News
- Clinical Trial Results
- FDA Drug Alerts
- FDA Consumer Updates
- New FDA Approvals
- New Drug Applications
- Drug Shortages
- Video Center
- Popular Articles
Professionals
Top 100 Drugs
- Abilify
- Acetaminophen
- Adderall
- Alprazolam
- Ambien
- Amitriptyline
- Amlodipine
- Amoxicillin
- Ativan
- Atorvastatin
- Avastin
- Azithromycin
- Baclofen
- Benadryl
- Benzonatate
- Biktarvy
- Botox
- Buprenorphine
- Bupropion
- Buspirone
- Cephalexin
- Cetirizine
- Ciprofloxacin
- Citalopram
- Clindamycin
- Clonazepam
- Clonidine
- Cyclobenzaprine
- Cymbalta
- Dexamethasone
- Diazepam
- Diclofenac
- Doxycycline
- Duloxetine
- Dupixent
- Eliquis
- Entyvio
- Epclusa
- Ezetimibe
- Famotidine
- Farxiga
- Fluoxetine
- Furosemide
- Gabapentin
- Humira
- Hydrochlorothiazide
- Hydrocodone
- Hydroxyzine
- Ibuprofen
- Januvia
- Jardiance
- Keytruda
- Klonopin
- Levothyroxine
- Lexapro
- Lisinopril
- Loratadine
- Lorazepam
- Losartan
- Lyrica
- Meloxicam
- Metformin
- Methadone
- Methylprednisolone
- Methocarbamol
- Methotrexate
- Metoprolol
- Metronidazole
- Miralax
- Mirtazapine
- Montelukast
- Mounjaro
- Mucinex
- Naloxone
- Naltrexone
- Naproxen
- Nitrofurantoin
- Omeprazole
- Opdivo
- Ondansetron
- Otezla
- Oxycodone
- Ozempic
- Pantoprazole
- Paxlovid
- Penicillin
- Percocet
- Phentermine
- Plan B
- Praluent
- Prednisone
- Promethazine
- Propranolol
- Prozac
- Qulipta
- Repatha
- Restasis
- Rexulti
- Semaglutide
- Seroquel
- Sertraline
- Sildenafil
- Skyrizi
- Soma
- Spironolactone
- Stelara
- Sublocade
- Suboxone
- Taltz
- Tamsulosin
- Tizanidine
- Toradol
- Tramadol
- Trazodone
- Trintellix
- Tylenol
- Ubrelvy
- Valium
- Venlafaxine
- Verzenio
- Viagra
- Vraylar
- Vyvanse
- Wegovy
- Wellbutrin
- Xanax
- Xolair
- Zofran
- Zoloft
- Zyrtec
